VALANX Biotech Alternatives & Competitors
12 companies similar to VALANX Biotech — Safer, more effective ADCs and protein-drug-conjugates with GoldenSite™ technolo...
Companies similar to VALANX Biotech
Araris Biotech AG
Building tomorrow's antibody-drug conjugates (ADCs)
Switzerland
AQEMIA
Scale drug discovery with quantum-inspired physics and generative AI
Paris, France
Biointron
Recombinant Antibody Expression, Delivery in 2 weeks (From Gene Sequence to Purified Antib...
China
Promatix Biosciences Ltd
Using multi-omics to develop the next generation of cancer therapeutics
London, United Kingdom
Rival Readout
Competing with VALANX Biotech? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
Avilar Therapeutics
Pioneering the discovery and development of extracellular protein degraders.
Waltham, United States
Evozyne
Evozyne designs novel therapeutic proteins with generative AI to solve immunology’s toughe...
Chicago, United States
Aureka Biotechnologies, Inc.
Inspire Therapeutic Design with Generative AI
Laguna Hills, United Stat...
Cradle
Engineer better proteins, faster.
Amsterdam, The Netherland...
bit.bio
The Cell Coding Company
Cambridge, United Kingdom
Broken String Biosciences
Powering the future of gene editing development.
Cambridge, United Kingdom
ProFound Therapeutics
Pioneering the expanded human proteome to reveal a universe of new medicines.
BDD
Redefining Early Stage Development
United Kingdom
About VALANX Biotech
VALANX Biotech, founded in 2017 and headquartered in Austria, is carving a niche in the Biotechnology, Health Care, and Pharmaceutical industries. The company's unique proposition lies in its GoldenSite™ technology. By offering a platform for site-specific conjugation, VALANX is reshaping how Antibody-Drug Conjugates (...
Optimized Protein Conjugation, ADCs Development, Therapeutic Window Enhancement, AI-Ready Dataset Preparation
Pharmaceutical Companies, Biotech Researchers, Drug Developers
GoldenSite Technology, Site-specific Conjugation, ADC Payloads, Metastatic Triple-negative-breast Cancer, Protein-drug-conjugates, Bioconjugation, Structurally Shielded Positions, Efficacy Enhancement, Off-target Interaction Reduction, LIV-1 Targeting, Differentiated ADCs, Novel Format Conjugates, Next Generation Bioconjugates
B2B, Platform, SaaS
Licensing, Product Sales, Service Fee
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around VALANX Biotech: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at VALANX Biotech on 12 Mar 2026. The 12 companies listed here were last checked between 11 Mar 2026 and 3 Aug 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
